Body mass index and cardiorenal outcomes in the EMPEROR-Preserved trial: Principal findings and meta-analysis with the DELIVER trial.

Naveed SattarJaved ButlerMatthew M Y LeeJosephine HarringtonAbhinav SharmaFaiez ZannadGerasimos FilippatosSubodh VermaJames L JanuzziJoão Pedro FerreiraStuart J PocockEgon PfarrAnne P OfstadMartina BrueckmannMilton PackerStefan D Anker

Published in: European journal of heart failure (2024)

Empagliflozin treatment resulted in broadly consistent cardiac effects across the range of BMI in patients with HFpEF. SGLT2i treatment yields benefit in patients with HFpEF regardless of baseline BMI.

Keyphrases

body mass index
study protocol
phase ii
type diabetes
randomized controlled trial
physical activity
heart failure
glycemic control